Parasite mitogen-activated protein kinases as drug discovery targets to treat human protozoan pathogens.
Parasite mitogen-activated protein kinases as drug discovery targets to treat human protozoan pathogens.
复制标题
DOI：
10.1155/2011/971968
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Curiel TJ
中科院分区：
文献类型：
--
作者：
Brumlik MJ;Pandeswara S;Ludwig SM;Murthy K;Curiel TJ
原生动物病原体是一组高度多样化的单细胞生物，其中一些是重要的人类病原体。一类原生动物病原体包括专性细胞内寄生虫，如疟疾、利什曼病、巴贝虫病和弓形体病的病原体。另一组包括细胞外病原体，如贾第虫病和阿米巴病的病原体。对于大多数人类原生动物病原体来说，一个不幸的统一主题是，通常缺乏针对它们的高效治疗方法。我们将审查靶向原生动物丝裂原活化蛋白激酶（MAPKs）作为一种新的药物发现方法，以开发更好的治疗方法，重点是疟原虫，利什曼原虫和弓形虫，其中最为人所知。
Protozoan pathogens are a highly diverse group of unicellular organisms, several of which are significant human pathogens. One group of protozoan pathogens includes obligate intracellular parasites such as agents of malaria, leishmaniasis, babesiosis, and toxoplasmosis. The other group includes extracellular pathogens such as agents of giardiasis and amebiasis. An unfortunate unifying theme for most human protozoan pathogens is that highly effective treatments for them are generally lacking. We will review targeting protozoan mitogen-activated protein kinases (MAPKs) as a novel drug discovery approach towards developing better therapies, focusing on Plasmodia, Leishmania, and Toxoplasma, about which the most is known.